Home Healthcare Pharmaceuticals Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others), Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others), Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Clinics, Home Care Settings), By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Benign Prostatic Hyperplasia Treatment Market, By Treatment Type 2022-2034 (USD MILLION/ Units)
    1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
    2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
    3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
  2. Benign Prostatic Hyperplasia Treatment Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Ambulatory Surgical Centers (ASCs)
    3. Clinics
    4. Home Care Settings
  3. Benign Prostatic Hyperplasia Treatment Market, By Distribution Channel: 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
  4. Regional Benign Prostatic Hyperplasia Treatment Market
    1. North America
      1. North America Benign Prostatic Hyperplasia Treatment Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
      2. North America Benign Prostatic Hyperplasia Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers (ASCs)
        3. Clinics
        4. Home Care Settings
      3. North America Benign Prostatic Hyperplasia Treatment Market By Distribution Channel: 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. U.S.
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      5. Canada
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
    2. Europe
      1. Europe Benign Prostatic Hyperplasia Treatment Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
      2. Europe Benign Prostatic Hyperplasia Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers (ASCs)
        3. Clinics
        4. Home Care Settings
      3. Europe Benign Prostatic Hyperplasia Treatment Market By Distribution Channel: 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. U.K.
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      5. Germany
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      6. France
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      7. Spain
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      8. Italy
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      9. Russia
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      10. Nordic
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      11. Benelux
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      12. Rest of Europe
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
    3. APAC
      1. APAC Benign Prostatic Hyperplasia Treatment Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
      2. APAC Benign Prostatic Hyperplasia Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers (ASCs)
        3. Clinics
        4. Home Care Settings
      3. APAC Benign Prostatic Hyperplasia Treatment Market By Distribution Channel: 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. China
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      5. Korea
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      6. Japan
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      7. India
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      8. Australia
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      9. Taiwan
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      10. South East Asia
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      11. Rest of Asia-Pacific
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
      2. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers (ASCs)
        3. Clinics
        4. Home Care Settings
      3. Middle East and Africa Benign Prostatic Hyperplasia Treatment Market By Distribution Channel: 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. UAE
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      5. Turkey
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      6. Saudi Arabia
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      7. South Africa
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      8. Egypt
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      9. Nigeria
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      10. Rest of MEA
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
    5. LATAM
      1. LATAM Benign Prostatic Hyperplasia Treatment Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
      2. LATAM Benign Prostatic Hyperplasia Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Ambulatory Surgical Centers (ASCs)
        3. Clinics
        4. Home Care Settings
      3. LATAM Benign Prostatic Hyperplasia Treatment Market By Distribution Channel: 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. Brazil
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      5. Mexico
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      6. Argentina
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      7. Chile
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      8. Colombia
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
      9. Rest of LATAM
        1. Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others)
        2. Minimally Invasive Procedures (Transurethral Resection of the Prostate [TURP], Laser Therapy, Prostatic Urethral Lift [UroLift], Prostatic Artery Embolisation [PAE], Others)
        3. Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)
        4. Hospitals
        5. Ambulatory Surgical Centers (ASCs)
        6. Clinics
        7. Home Care Settings
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Online Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.